BCIQ Profiles

Company Profile Report

Kite reports additional Phase I ZUMA-3 data of axicabtagene ciloleucel in ALL

Kite Pharma Inc. (NASDAQ:KITE) reported data from 11 evaluable patients with relapsed or refractory B precursor acute lymphoblastic leukemia (ALL) in the Phase I portion of the Phase I/II ZUMA-3 trial showing that axicabtagene ciloleucel (KTE-C19) led to complete remission or

Read the full 414 word article

How to gain access

Continue reading with a
two-week free trial.